Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients

Bibliography

• Ohnota H, Koizumi T, Tsutstumi N, et al. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther 1994;269:489-95
   PubMed Web of Science ®Google Scholar
• Mogami H, Shibata H, Nobusawa R, et al. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in pancreatic β-cell line, MIN 6 cell. Eur J Pharmacol 1994;269:293-8
   PubMed Web of Science ®Google Scholar
• Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Ionophoretic activity of meglitinide analogues. Diabetes Res 1994;27:61-71
   PubMedGoogle Scholar
• Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency. Diabetes Res 1994;27:81-7
   PubMedGoogle Scholar
• Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res 1995;27:263-6
   PubMed Web of Science ®Google Scholar
• Geisen K, Hitzel V, Ökomonopoulos R, et al. Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics. Arzneim Forsch Drug Res 1985;35:707-12
   PubMed Web of Science ®Google Scholar
• Adis RD Profile. Mitiglinide K 1229, S 21403. Drugs R&D 2004;6:98-101
   Google Scholar
• Lins L, Brasseur R, Malaisse WJ. Conformation analysis of the calcium complexes formed by meglitinide analogs. Res Commun Mol Pathol Pharmacol 1995;90:153-64
   PubMedGoogle Scholar
• Lins L, Brasseur R, Malaisse WJ, et al. Importance of the hydrophobic energy: structural determinant of a hypoglycemic drug of the meglitinide family by nuclear magnetic resonance and molecular modelling. Biochem Pharmacol 1996;52:1155-68
   PubMed Web of Science ®Google Scholar
• Malaisse WJ, Bakkali Nadi A, Malaisse-Lagae F, et al. Insulinotropic action of (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate. II. Ionophoretic and conformational aspects. Gen Pharmac 1995;26:1319-25
   PubMedGoogle Scholar
• Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Ionophoretic properties of the non-sulphonylurea hypoglycaemic agents A-4166 and KAD-1229. Res Commun Mol Pathol Pharmacol 1995;88:339-47
   PubMedGoogle Scholar
• Yu L, Zeng S. Determination of mitiglinide in rat plasma by high-performance liquid chromatography with UV detection. J Chromatogr 2006;834:204-7
   Google Scholar
• Liang J, Tian Y, Zhang Z, et al. High-performance liquid chromatography-electrospray ionization mass spectrometry determination of mitiglinide in human plasma and its pharmacokinetics. J Mass Spectrom 2007;42:171-7
   PubMed Web of Science ®Google Scholar
• Yu L, Lu S, Lin Y, Zeng S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol 2007;73:1842-51
   PubMed Web of Science ®Google Scholar
• Malaisse WJ, Dard-Brunelle D. Binding of tritiated S21403 to an artificial phospholipid bilayer. Res Commun Mol Pathol Pharmacol 1999;103:268-74
   Google Scholar
• Malaisse WJ, Malaisse-Lagae F. Uptake of tritiated mitiglinide by pancreatic pieces and islets. Diabetes Res 2000;35:51-9
   Google Scholar
• Reinmann F, Proks P, Ashcroft FM. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol 2001;132:1542-8
   PubMed Web of Science ®Google Scholar
• Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 2001;431:119-25
   PubMed Web of Science ®Google Scholar
• Cai Z, Lansdell KA, Sheppard DN. Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl- channels by non-sulphonylurea hypoglycaemic agents. Br J Pharmacol 1999;128: 108-18
   PubMed Web of Science ®Google Scholar
• Boom A, Lybaert P, Pollet J-F, et al. Expression and localization of cystic fibrosis transmembrane conductance regulator in the endocrine pancreas. Endocrine 2007;32:197-205
   PubMed Web of Science ®Google Scholar
• Malaisse WJ, Sato F. Insulinotropic action of (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate. I. Secretory and cationic aspects. Gen Pharmac 1995;26:1313-8
   PubMedGoogle Scholar
• Ulusoy S, Malaisse WJ. Effect of the meglitinide analogue KAD-1229 on 45Ca outflow and insulin release in pancreatic islets. Diabetes Res 1996;31:27-31
   Google Scholar
• Louchami K, Jijakli H, Malaisse WJ. Effect of the meglitinide analog S21403 on cationic fluxes and insulin release in perifused rat pancreatic islets exposed to a high concentration of D-glucose. Pharmacol Res 1999;40:297-300
   PubMed Web of Science ®Google Scholar
• Ohnota H, Kobayashi M, Koizumi T, et al. In vitro insulinotropic action of a new non-sulfonylurea hypoglycemic agent, calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl-carbonyl) propionate dihydrate (KAD-1229), in rat pancreatic B-cells. Biochem Pharmacol 1995;49:165-71
   PubMed Web of Science ®Google Scholar
• Kinukawa M, Ohnota H, Ajisawa Y. Effect of a non-sulphonylurea hypoglycaemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat. Br J Pharmacol 1996;117:1702-6
   PubMed Web of Science ®Google Scholar
• Gregorio F, Ambrosi F, Boemi M, et al. Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations. Eur J Pharmacol 2002;456:141-7
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Yamato T, Tsuji A, et al. Study of the insulinotropic effect of the novel antihyperglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line. Arzneim Forsh Drug Res 2002;52:605-9
   PubMed Web of Science ®Google Scholar
• Kaiser N, Nesher R, Oprescu A, et al. Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic β-cells. Br J Pharmacol 2005;146:872-81
   PubMed Web of Science ®Google Scholar
• Nagamatsu S, Ohara-Imaizumi M, Nakamichi Y, et al. Imaging docking and fusion of insulin granules induced by antidiabetes agents. Sulfonylurea and glinide durgs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules. Diabetes 2006;55:2819-25
   PubMed Web of Science ®Google Scholar
• Shigeto M, Katsura M, Matsuda M, et al. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther 2007;322:1-7
   PubMed Web of Science ®Google Scholar
• Nakashima E, Nakamura J, Koh N, et al. Effect of a novel hypoglycemic agent, KAD-1229 on glucose metabolism and fructose-2,6-bisphosphate content in isolated hepatocytes of normal rats. Diab Res Clin Pract 1996;34:13-22
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Maruyama K, Murakami M, et al. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent. Eur J Pharmacol 2001;431:331-8
   PubMed Web of Science ®Google Scholar
• Maruyama I, Tomiyama Y, Maruyama K, et al. Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. Eur J Pharmacol 2006;531:194-200
   PubMed Web of Science ®Google Scholar
• Ogawa K, Ikewaki K, Taniguchi I, et al. Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hears. Int Heart J 2007;48:337-45
   PubMed Web of Science ®Google Scholar
• Ohnota H, Koizumi T, Kobayashi M, et al. Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats. Can J Physiol Pharmacol 1995;73:1-6
   PubMed Web of Science ®Google Scholar
• Ohnota H, Kitamura T, Kinukawa M, et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Jpn J Pharmacol 1996;71:315-23
   PubMedGoogle Scholar
• Ichikawa K, Yamato T, Ojima K, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2002;29:423-7
   PubMed Web of Science ®Google Scholar
• Misawa K, Ichikawa K, Ojima K, et al. Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Pharmacology 2001;62:65-72
   PubMed Web of Science ®Google Scholar
• Mori Y, Ojima K, Fujimori Y, et al. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine 2006;29:309-15
   PubMed Web of Science ®Google Scholar
• Yoshihara T, Kumashiro N, Kanazawa Y, et al. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J 2006;53:67-72
   PubMed Web of Science ®Google Scholar
• Kumashiro N, Yoshihara T, Kanazawa Y, et al. Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 2007;54:163-6
   PubMed Web of Science ®Google Scholar
• Yamada S, Watanabe M, Funae O, et al. Effect of combination therapy of a rapid-acting insulin secretagogues (glinide) with premixed insulin in type 2 diabetes mellitus. Int Med 2007;46:1893-7
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Kannno S, Ishimura I, Node K. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Met Clin Exp 2007;56:1458-63
   Google Scholar
• Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005;48:1919-24
   PubMed Web of Science ®Google Scholar
• Dunning BE. New non-sulfonylurea insulin secretagogues. Exp Opin Invest Drugs 1997;6:1041-8
   PubMedGoogle Scholar
• Pratley RE, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des 2001;7:1375-97
   PubMed Web of Science ®Google Scholar
• Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16
   PubMed Web of Science ®Google Scholar